Roche increases IPF presence with $1.39bn Promedior buy

Roche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for the deadly lung-scarring disease idiopathic pulmonary fibrosis (IPF) in a deal wort

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP a...

AZ fleshes out positive trial of revitalised lupus drug anif...

Roche joins others in dropping myostatin inhibitor for DMD

First Rituxan biosimilar Truxima set to make its debut in US

Roche swoops on Dicerna’s gene-silencing hepatitis B drug